AbCellera Biologics and Dermata Therapeutics: A Biotech Comparison

Analysts see greater upside potential in Dermata Therapeutics despite AbCellera's stronger financials.

Apr. 15, 2026 at 11:48am

Got story updates? Submit your updates here. ›

An extreme close-up of complex medical laboratory instruments and machinery, conveying the high-tech, high-stakes nature of the biotech industry through dramatic lighting and industrial textures.Cutting-edge biotech equipment symbolizes the competitive race to develop the next breakthrough medical treatment.San Diego Today

AbCellera Biologics (NASDAQ:ABCL) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap medical companies, but analysts believe Dermata Therapeutics has more favorable growth prospects despite AbCellera's stronger profitability and institutional backing.

Why it matters

The comparison highlights the nuances in evaluating early-stage biotech firms, where factors like pipeline potential, valuation, and market positioning can outweigh current financial metrics. Investors will be watching to see which company can most effectively translate its research into commercial success.

The details

AbCellera Biologics has a consensus price target of $8.40, suggesting 123% upside, while Dermata Therapeutics has a $10 target, implying 700% potential gains. Dermata has lower revenue but higher earnings than AbCellera, and its stock is more volatile. AbCellera has stronger institutional ownership at 61.4% versus just 8.7% for Dermata.

  • AbCellera Biologics and Dermata Therapeutics are both publicly traded on the Nasdaq exchange.

The players

AbCellera Biologics

An antibody drug discovery and development company headquartered in Vancouver, Canada.

Dermata Therapeutics

A late-stage medical dermatology company focused on identifying and commercializing treatments for skin conditions, headquartered in San Diego, California.

Got photos? Submit your photos here. ›

The takeaway

This comparison highlights the nuanced factors investors must weigh when evaluating early-stage biotech firms, where pipeline potential and market positioning can be more important than current financial metrics. The contrasting fortunes of AbCellera and Dermata demonstrate the risks and rewards in this volatile sector.